Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.
Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
Newborn Calf Barely Survives Freezing Cold, Then Finds Warmth With Kids
A Powerful Moment As Buddhist Monks Stop To Bless A Nonverbal Boy With Autism
Lost For 65 Days In The Freezing Cold, This Brave Senior Dog Survived Against The Odds
He Says His Sister's Dog Hates Him — And The Pictures Don't Lie
An Old Man Kept Visiting A Bookstore Every Saturday—The Reason Has People In Tears
NYC Food Influencer Reviews A Struggling Family Restaurant And Brings It Back To Life
Catherine O'Hara Reveals The Only Role She Wants To Be Remembered For
This Apology During A Volleyball Game Is The Best Apology You Will See Today
This Family Built A Colorful Igloo And It’s Magical
This 9-Year-Old Piano Prodigy Is Going Viral
